Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TTP399: Phase IIa data

TransTech said data from a Phase IIa trial in 128 Type II diabetics on stable doses of metformin showed that TTP399 significantly reduced HbA1c

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE